<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340080</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>A Serum Multi-Parametric Analysis Identifies an Early Innate Immune Signature Associated to Increased Vaccine-Specific Antibody Production and Seroconversion in Simultaneous COVID-19 mRNA and Cell-Based Quadrivalent Influenza Vaccination.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1050</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091050</ELocationID><Abstract><AbstractText>In this pilot study, a multi-parametric analysis comparing immune responses in sera of adult healthy subjects (HS) or people with type 2 diabetes mellitus (T2D) undergoing the single or simultaneous administration of mRNA-based COVID-19 and cellular quadrivalent inactivated influenza vaccines was conducted. While SARS-CoV-2 antibodies remains comparable, influenza antibody titers and seroconversion were significantly higher upon simultaneous vaccination. Magnitude of anti-influenza humoral response closely correlated with an early innate immune signature, previously described for the COVID-19 vaccine, composed of IL-15, IL-6, TNF-α, IFN-γ, CXCL-10 and here extended also to acute-phase protein Pentraxin 3. People with T2D receiving simultaneous vaccination showed a protective response comparable to HS correlating with the early induction of IFN-γ/CXCL10 and a significant reduction of the circulating glucose level due to increased oxidation of glucose digestion and consumption. These data, although preliminary and in-need of validation in larger cohorts, might be exploited to optimize future vaccination in people with chronic disorders, including diabetes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Severa</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0411-4545</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricci</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8445-512X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etna</LastName><ForeName>Marilena Paola</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0003-2551-393X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Facchini</LastName><ForeName>Marzia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puzelli</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fedele</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0017-6711</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iorio</LastName><ForeName>Egidio</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6673-3838</Identifier><AffiliationInfo><Affiliation>High Resolution NMR Unit, Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairo</LastName><ForeName>Giada</ForeName><Initials>G</Initials><Identifier Source="ORCID">0009-0005-9230-6115</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castrechini</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ASL ROMA 1, Regione Lazio, 00145 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ungari</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>ASL ROMA 1, Regione Lazio, 00145 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iannetta</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6938-8627</Identifier><AffiliationInfo><Affiliation>Infectious Disease Clinic, Tor Vergata University Hospital, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leone</LastName><ForeName>Pasqualina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chirico</LastName><ForeName>Mattea</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3447-5077</Identifier><AffiliationInfo><Affiliation>High Resolution NMR Unit, Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisanu</LastName><ForeName>Maria Elena</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>High Resolution NMR Unit, Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottazzi</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1930-9257</Identifier><AffiliationInfo><Affiliation>Department of Inflammation and Immunology, Humanitas Clinical and Research Centre-IRCCS, 20019 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedetti</LastName><ForeName>Livia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0001-8346-1130</Identifier><AffiliationInfo><Affiliation>Infectious Disease Clinic, Tor Vergata University Hospital, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sali</LastName><ForeName>Michela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3609-2990</Identifier><AffiliationInfo><Affiliation>Department of Laboratory and Infectious Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic Biotechnological Sciences, Intensive and Perioperative Clinics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartolomucci</LastName><ForeName>Remo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ASL ROMA 1, Regione Lazio, 00145 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balducci</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Metabolic Fitness Association, Monterotondo, 00015 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garlanda</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1510-7703</Identifier><AffiliationInfo><Affiliation>Department of Inflammation and Immunology, Humanitas Clinical and Research Centre-IRCCS, 20019 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, 20090 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefanelli</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spadea</LastName><ForeName>Antonietta</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-2054-5155</Identifier><AffiliationInfo><Affiliation>ASL ROMA 1, Regione Lazio, 00145 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palamara</LastName><ForeName>Anna Teresa</ForeName><Initials>AT</Initials><Identifier Source="ORCID">0000-0001-8330-4381</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coccia</LastName><ForeName>Eliana Marina</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-1606-2949</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Project no. PE00000007, INF-ACT</GrantID><Agency>Project no. PE00000007, INF-ACT</Agency><Country /></Grant><Grant><GrantID>RIPrEI project, L106/2021</GrantID><Agency>Italian Ministry of Health</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">influenza virus</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Marco Iannetta reports research funding (to the Institution) from Gilead, GSK and BD Biosciences for unrelated work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340080</ArticleId><ArticleId IdType="pmc">PMC11436141</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091050</ArticleId><ArticleId IdType="pii">vaccines12091050</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Townsend J.P., Hassler H.B., Lamb A.D., Sah P., Nishio A.A., Nguyen C., Tew A.D., Galvani A.P., Dornburg A. Seasonality of endemic COVID-19. mBio. 2023;14:e0142623. doi: 10.1128/mbio.01426-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01426-23</ArticleId><ArticleId IdType="pmc">PMC10746271</ArticleId><ArticleId IdType="pubmed">37937979</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  Factsheet about Seasonal Influenza.  [(accessed on 28 August 2024)].  Available online:  https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet.</Citation></Reference><Reference><Citation>Hause A.M., Zhang B., Yue X., Marquez P., Myers T.R., Parker C., Gee J., Su J., Shimabukuro T.T., Shay D.K. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US. JAMA Netw. Open. 2022;5:e2222241. doi: 10.1001/jamanetworkopen.2022.22241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.22241</ArticleId><ArticleId IdType="pmc">PMC9287747</ArticleId><ArticleId IdType="pubmed">35838667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenigsberg T.A., Goddard K., Hanson K.E., Lewis N., Klein N., Irving S.A., Naleway A.L., Crane B., Kauffman T.L., Xu S., et al. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023;41:5678–5682. doi: 10.1016/j.vaccine.2023.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.08.023</ArticleId><ArticleId IdType="pmc">PMC10661699</ArticleId><ArticleId IdType="pubmed">37599140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus R., Baos S., Cappel-Porter H., Carson-Stevens A., Clout M., Culliford L., Emmett S.R., Garstang J., Gbadamoshi L., Hallis B., et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): A multicentre, randomised, controlled, phase 4 trial. Lancet. 2021;398:2277–2287. doi: 10.1016/S0140-6736(21)02329-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02329-1</ArticleId><ArticleId IdType="pmc">PMC8585490</ArticleId><ArticleId IdType="pubmed">34774197</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart A.S.V., Shaw R.H., Liu X., Greenland M., Aley P.K., Andrews N.J., Cameron J.C., Charlton S., A Clutterbuck E., Collins A.M., et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): A single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2022;399:36–49. doi: 10.1016/S0140-6736(21)02718-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02718-5</ArticleId><ArticleId IdType="pmc">PMC8648333</ArticleId><ArticleId IdType="pubmed">34883053</ArticleId></ArticleIdList></Reference><Reference><Citation>Toback S., Galiza E., Cosgrove C., Galloway J., Goodman A.L., Swift P.A., Rajaram S., Graves-Jones A., Edelman J., Burns F., et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2022;10:167–179. doi: 10.1016/S2213-2600(21)00409-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00409-4</ArticleId><ArticleId IdType="pmc">PMC8598212</ArticleId><ArticleId IdType="pubmed">34800364</ArticleId></ArticleIdList></Reference><Reference><Citation>Izikson R., Brune D., Bolduc J.S., Bourron P., Fournier M., Moore T.M., Pandey A., Perez L., Sater N., Shrestha A., et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥ 65 years: A phase 2, randomised, open-label study. Lancet Respir. Med. 2022;10:392–402. doi: 10.1016/S2213-2600(21)00557-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00557-9</ArticleId><ArticleId IdType="pmc">PMC8803382</ArticleId><ArticleId IdType="pubmed">35114141</ArticleId></ArticleIdList></Reference><Reference><Citation>Marín-Hernández D., Nixon D.F., Hupert N. Heterologous vaccine interventions: Boosting immunity against future pandemics. Mol. Med. 2021;27:54. doi: 10.1186/s10020-021-00317-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-021-00317-z</ArticleId><ArticleId IdType="pmc">PMC8165337</ArticleId><ArticleId IdType="pubmed">34058986</ArticleId></ArticleIdList></Reference><Reference><Citation>Domnich A., Orsi A., Trombetta C.-S., Guarona G., Panatto D., Icardi G. COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy. Pharmaceuticals. 2022;15:322. doi: 10.3390/ph15030322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15030322</ArticleId><ArticleId IdType="pmc">PMC8952219</ArticleId><ArticleId IdType="pubmed">35337120</ArticleId></ArticleIdList></Reference><Reference><Citation>Severa M., Rizzo F., Sinigaglia A., Ricci D., Etna M.P., Cola G., Landi D., Buscarinu M.C., Valdarchi C., Ristori G., et al. A specific anti-COVID-19 BNT162b2 vaccine-induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients. Clin. Transl. Immunol. 2023;12:e1434. doi: 10.1002/cti2.1434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1434</ArticleId><ArticleId IdType="pmc">PMC10036198</ArticleId><ArticleId IdType="pubmed">36969367</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam P.S., Scott M.K.D., Hagan T., Li C., Feng Y., Wimmers F., Grigoryan L., Trisal M., Edara V.V., Lai L., et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021;596:410–416. doi: 10.1038/s41586-021-03791-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03791-x</ArticleId><ArticleId IdType="pmc">PMC8761119</ArticleId><ArticleId IdType="pubmed">34252919</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi C., Terpos E., Rosati M., Angel M., Bear J., Stellas D., Karaliota S., Apostolakou F., Bagratuni T., Patseas D., et al. Systemic IL-15, IFN-gamma, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36:109504. doi: 10.1016/j.celrep.2021.109504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109504</ArticleId><ArticleId IdType="pmc">PMC8299183</ArticleId><ArticleId IdType="pubmed">34352226</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucasas K.L., Franco L.M., Shaw C.A., Bray M.S., Wells J.M., Niño D., Arden N., Quarles J.M., Couch R.B., Belmont J.W. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J. Infect. Dis. 2011;203:921–929. doi: 10.1093/infdis/jiq156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiq156</ArticleId><ArticleId IdType="pmc">PMC3068032</ArticleId><ArticleId IdType="pubmed">21357945</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Rouphael N., Duraisingham S., Romero-Steiner S., Presnell S., Davis C., Schmidt D.S., E Johnson S., Milton A., Rajam G., et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 2014;15:195–204. doi: 10.1038/ni.2789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2789</ArticleId><ArticleId IdType="pmc">PMC3946932</ArticleId><ArticleId IdType="pubmed">24336226</ArticleId></ArticleIdList></Reference><Reference><Citation>I Nakaya H., Wrammert J., Lee E.K., Racioppi L., Marie-Kunze S., Haining W.N., Means A.R., Kasturi S.P., Khan N., Li G.-M., et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 2011;12:786–795. doi: 10.1038/ni.2067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2067</ArticleId><ArticleId IdType="pmc">PMC3140559</ArticleId><ArticleId IdType="pubmed">21743478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosati M., Terpos E., Homan P., Bergamaschi C., Karaliota S., Ntanasis-Stathopoulos I., Devasundaram S., Bear J., Burns R., Bagratuni T., et al. Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations. Front. Immunol. 2023;14:1292568. doi: 10.3389/fimmu.2023.1292568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1292568</ArticleId><ArticleId IdType="pmc">PMC10711274</ArticleId><ArticleId IdType="pubmed">38090597</ArticleId></ArticleIdList></Reference><Reference><Citation> [(accessed on 28 August 2024)].  Available online:  https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2021-2022/202102_recommendation.pdf.</Citation></Reference><Reference><Citation>Fedele G., Trentini F., Schiavoni I., Abrignani S., Antonelli G., Baldo V., Baldovin T., Bandera A., Bonura F., Clerici P., et al. Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. Front. Immunol. 2022;13:1021396. doi: 10.3389/fimmu.2022.1021396.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1021396</ArticleId><ArticleId IdType="pmc">PMC9661524</ArticleId><ArticleId IdType="pubmed">36389704</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. World Health Organization; Geneva, Switzerland: 2011.  [(accessed on 23 August 2012)]. Global Influenza Surveillance Network. Available online:  http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf.</Citation></Reference><Reference><Citation>The European Agency for the Evaluation of Medicinal Products (EMEA)-Committee for Proprietary Medicinal Products (CPMP) Cell Cultured Inactivated Influenza Vaccines. Annex to Note for Guidance on Harmonization of Requirements for Influenza Vaccines (CPMP/BWP/214/96) CPMP/BWP/2490/00; EMEA; London, UK: 2002.</Citation></Reference><Reference><Citation>The European Agency for the Evaluation of Medicinal Products (EMEA)-Committee for Proprietary Medicinal Products (CPMP) Note for Guidance on Harmonization of Requirements for Influenza Vaccines. CPMP/BWP/214/96; EMEA; London, UK: 1997.</Citation></Reference><Reference><Citation>Brunetta E., Folci M., Bottazzi B., De Santis M., Gritti G., Protti A., Mapelli S.N., Bonovas S., Piovani D., Leone R., et al. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat. Immunol. 2021;22:19–24. doi: 10.1038/s41590-020-00832-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00832-x</ArticleId><ArticleId IdType="pubmed">33208929</ArticleId></ArticleIdList></Reference><Reference><Citation>Palleschi S., Guglielmi V., Nisticò L., Ferreri C., Tabolacci C., Facchiano F., Iorio E., Giuliani A., Brescianini S., Medda E., et al. A multi-marker integrative analysis reveals benefits and risks of bariatric surgery. Sci. Rep. 2022;12:18877. doi: 10.1038/s41598-022-23241-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-23241-6</ArticleId><ArticleId IdType="pmc">PMC9640526</ArticleId><ArticleId IdType="pubmed">36344536</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottazzi B., Santini L., Savino S., Giuliani M.M., Díez A.I.D., Mancuso G., Beninati C., Sironi M., Valentino S., Deban L., et al. Recognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant. PLoS ONE. 2015;10:e0120807. doi: 10.1371/journal.pone.0120807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0120807</ArticleId><ArticleId IdType="pmc">PMC4364741</ArticleId><ArticleId IdType="pubmed">25786110</ArticleId></ArticleIdList></Reference><Reference><Citation>Garlanda C., Bottazzi B., Magrini E., Inforzato A., Mantovani A. PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer. Physiol. Rev. 2018;98:623–639. doi: 10.1152/physrev.00016.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00016.2017</ArticleId><ArticleId IdType="pmc">PMC5985957</ArticleId><ArticleId IdType="pubmed">29412047</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner J., Lewis D.J.M., Maertzdorf J., Mollenkopf H.-J., Bodinham C., Pizzoferro K., Linley C., Greenwood A., Mantovani A., Bottazzi B., et al. Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: Randomized controlled clinical trials conducted by the BIOVACSAFE consortium. Sci. Rep. 2019;9:20362. doi: 10.1038/s41598-019-56994-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-56994-8</ArticleId><ArticleId IdType="pmc">PMC6937244</ArticleId><ArticleId IdType="pubmed">31889148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonanni P., Steffen R., Schelling J., Balaisyte-Jazone L., Posiuniene I., Zatoński M., Van Damme P. Vaccine co-administration in adults: An effective way to improve vaccination coverage. Hum. Vaccines Immunother. 2023;19:2195786. doi: 10.1080/21645515.2023.2195786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2195786</ArticleId><ArticleId IdType="pmc">PMC10142308</ArticleId><ArticleId IdType="pubmed">37039318</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolhain J., Janssens W., Dindore V., Mihalyi A. Infant vaccine co-administration: Review of 18 years of experience with GSK’s hexavalent vaccine co-administered with routine childhood vaccines. Expert. Rev. Vaccines. 2020;19:419–443. doi: 10.1080/14760584.2020.1758560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2020.1758560</ArticleId><ArticleId IdType="pubmed">32419537</ArticleId></ArticleIdList></Reference><Reference><Citation>Börner N., Mühlberger N., Jelinek T. Tolerability of multiple vaccinations in travel medicine. J. Travel. Med. 2003;10:112–116. doi: 10.2310/7060.2003.31690.</Citation><ArticleIdList><ArticleId IdType="doi">10.2310/7060.2003.31690</ArticleId><ArticleId IdType="pubmed">12650655</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Coadministration of Seasonal Inactivated Influenza and COVID-19 Vaccines: Interim Guidance.  [(accessed on 8 August 2021)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-coadministration-influenza-vaccines.</Citation></Reference><Reference><Citation>Focosi D. From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses. Vaccines. 2023;11:109. doi: 10.3390/vaccines11010109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11010109</ArticleId><ArticleId IdType="pmc">PMC9860680</ArticleId><ArticleId IdType="pubmed">36679954</ArticleId></ArticleIdList></Reference><Reference><Citation>Circular of the Italian Ministry of Health.  [(accessed on 28 August 2024)];Prevenzione e controllo Dell’influenza: Raccomandazioni per la Stagione 2023–2024.  Available online:  https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2023&amp;codLeg=93294&amp;parte=1%20&amp;serie=null.</Citation></Reference><Reference><Citation>Janssen C., Mosnier A., Gavazzi G., Combadière B., Crépey P., Gaillat J., Launay O., Botelho-Nevers E. Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies. Hum. Vaccines Immunother. 2022;18:2131166. doi: 10.1080/21645515.2022.2131166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2131166</ArticleId><ArticleId IdType="pmc">PMC9746457</ArticleId><ArticleId IdType="pubmed">36256633</ArticleId></ArticleIdList></Reference><Reference><Citation>Verket M., Jacobsen M., Schütt K., Marx N., Müller-Wieland D. Influenza vaccination in patients affected by diabetes. Eur. Heart J. Suppl. 2023;25:A36–A41. doi: 10.1093/eurheartjsupp/suac119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartjsupp/suac119</ArticleId><ArticleId IdType="pmc">PMC10021494</ArticleId><ArticleId IdType="pubmed">36937371</ArticleId></ArticleIdList></Reference><Reference><Citation>Warpechowski J., Leszczyńska P., Juchnicka D., Olichwier A., Szczerbiński Ł., Krętowski A.J. Assessment of the Immune Response in Patients with Insulin Resistance, Obesity, and Diabetes to COVID-19 Vaccination. Vaccines. 2023;11:1203. doi: 10.3390/vaccines11071203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11071203</ArticleId><ArticleId IdType="pmc">PMC10383449</ArticleId><ArticleId IdType="pubmed">37515018</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca D., Diaz A., Romero M., Mendez N.V., Landin A.M., Ryan J.G., Blomberg B.B. Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine. 2013;31:3603–3610. doi: 10.1016/j.vaccine.2013.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.003</ArticleId><ArticleId IdType="pmc">PMC3760593</ArticleId><ArticleId IdType="pubmed">23711934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz P.L.D., Bakken I.J., Håberg S.E., Tapia G., Hauge S.H., Birkeland K.I., Gulseth H.L., Stene L.C. Higher frequency of hospitalization but lower relative mortality for pandemic influenza in people with type 2 diabetes. J. Intern. Med. 2020;287:78–86. doi: 10.1111/joim.12984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12984</ArticleId><ArticleId IdType="pubmed">31587396</ArticleId></ArticleIdList></Reference><Reference><Citation>Remschmidt C., Wichmann O., Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: Systematic review and meta-analysis. BMC Med. 2015;13:53. doi: 10.1186/s12916-015-0295-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0295-6</ArticleId><ArticleId IdType="pmc">PMC4373029</ArticleId><ArticleId IdType="pubmed">25857236</ArticleId></ArticleIdList></Reference><Reference><Citation>Soetedjo N.N.M., Iryaningrum M.R., Lawrensia S., Permana H. Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review. Diabetes Metab. Syndr. Clin. Res. Rev. 2022;16:102406. doi: 10.1016/j.dsx.2022.102406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2022.102406</ArticleId><ArticleId IdType="pmc">PMC8776339</ArticleId><ArticleId IdType="pubmed">35104750</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal R., Sachdeva N., Mukherjee S., Suri V., Zohmangaihi D., Ram S., Puri G.D., Bhalla A., Soni S.L., Pandey N., et al. Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report. Diabetes Metab. Syndr. Clin. Res. Rev. 2021;15:193–196. doi: 10.1016/j.dsx.2020.12.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.12.035</ArticleId><ArticleId IdType="pmc">PMC7762626</ArticleId><ArticleId IdType="pubmed">33385765</ArticleId></ArticleIdList></Reference><Reference><Citation>Virgilio E., Trevisan C., Abbatecola A., Malara A., Palmieri A., Fedele G., Stefanelli P., Leone P., Schiavoni I., Maggi S., et al. Diabetes Affects Antibody Response to SARS-CoV-2 Vaccination in Older Residents of Long-term Care Facilities: Data From the GeroCovid Vax Study. Diabetes Care. 2022;45:2935–2942. doi: 10.2337/dc22-1255.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc22-1255</ArticleId><ArticleId IdType="pubmed">36201657</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochida Y., Uchida S. mRNA vaccine designs for optimal adjuvanticity and delivery. RNA Biol. 2024;21:1–27. doi: 10.1080/15476286.2024.2333123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2024.2333123</ArticleId><ArticleId IdType="pmc">PMC10968337</ArticleId><ArticleId IdType="pubmed">38528828</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó K., Buckstein M., Ni H., Weissman D. Suppression of RNA recognition by toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23:165–175. doi: 10.1016/j.immuni.2005.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.06.008</ArticleId><ArticleId IdType="pubmed">16111635</ArticleId></ArticleIdList></Reference><Reference><Citation>Alameh M.-G., Tombácz I., Bettini E., Lederer K., Ndeupen S., Sittplangkoon C., Wilmore J.R., Gaudette B.T., Soliman O.Y., Pine M., et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54:2877–2892. doi: 10.1016/j.immuni.2021.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.11.001</ArticleId><ArticleId IdType="pmc">PMC8566475</ArticleId><ArticleId IdType="pubmed">34852217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Zhu H., Gan J., Liang G., Li L., Zhao Y. Engineered mRNA Delivery Systems for Biomedical Applications. Adv. Mater. 2023;36:e2308029. doi: 10.1002/adma.202308029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202308029</ArticleId><ArticleId IdType="pubmed">37805865</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato M., Werba J.P., Frigerio B., Coggi D., Sansaro D., Ravani A., Ferrante P., Veglia F., Tremoli E., Baldassarre D. Relationship between Influenza Vaccination Coverage Rate and COVID-19 Outbreak: An Italian Ecological Study. Vaccines. 2020;8:535. doi: 10.3390/vaccines8030535.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030535</ArticleId><ArticleId IdType="pmc">PMC7563271</ArticleId><ArticleId IdType="pubmed">32947988</ArticleId></ArticleIdList></Reference><Reference><Citation>Marín-Hernández D., Schwartz R.E., Nixon D.F. Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. J. Med. Virol. 2021;93:64–65. doi: 10.1002/jmv.26120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26120</ArticleId><ArticleId IdType="pmc">PMC7300995</ArticleId><ArticleId IdType="pubmed">32497290</ArticleId></ArticleIdList></Reference><Reference><Citation>Debisarun P.A., Gössling K.L., Bulut O., Kilic G., Zoodsma M., Liu Z., Oldenburg M., Rüchel N., Zhang B., Xu C.-J., et al. Induction of trained immunity by influenza vaccination—Impact on COVID-19. PLOS Pathog. 2021;17:e1009928. doi: 10.1371/journal.ppat.1009928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009928</ArticleId><ArticleId IdType="pmc">PMC8568262</ArticleId><ArticleId IdType="pubmed">34695164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Liu M., Liu J. The Association between Influenza Vaccination and COVID-19 and Its Outcomes: A Systematic Review and Meta-Analysis of Observational Studies. Vaccines. 2021;9:529. doi: 10.3390/vaccines9050529.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9050529</ArticleId><ArticleId IdType="pmc">PMC8161076</ArticleId><ArticleId IdType="pubmed">34065294</ArticleId></ArticleIdList></Reference><Reference><Citation>Sánchez-Ramón S., Conejero L., Netea M.G., Sancho D., Palomares O., Subiza J.L. Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. Front. Immunol. 2018;9:2936. doi: 10.3389/fimmu.2018.02936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02936</ArticleId><ArticleId IdType="pmc">PMC6304371</ArticleId><ArticleId IdType="pubmed">30619296</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekkering S., Domínguez-Andrés J., Joosten L.A., Riksen N.P., Netea M.G. Trained Immunity: Reprogramming Innate Immunity in Health and Disease. Annu. Rev. Immunol. 2021;39:667–693. doi: 10.1146/annurev-immunol-102119-073855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-102119-073855</ArticleId><ArticleId IdType="pubmed">33637018</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser N., Legrand-Poels S., Piette J., Scheen A.J., Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res. Clin. Pr. 2014;105:141–150. doi: 10.1016/j.diabres.2014.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2014.04.006</ArticleId><ArticleId IdType="pubmed">24798950</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari M., Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018;26:685–698. doi: 10.1007/s10787-018-0458-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-018-0458-0</ArticleId><ArticleId IdType="pubmed">29508109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., O’Hagan D., Rappuoli R., De Gregorio E. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. USA. 2008;105:10501–10506. doi: 10.1073/pnas.0804699105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0804699105</ArticleId><ArticleId IdType="pmc">PMC2483233</ArticleId><ArticleId IdType="pubmed">18650390</ArticleId></ArticleIdList></Reference><Reference><Citation>Chorny A., Casas-Recasens S., Sintes J., Shan M., Polentarutti N., García-Escudero R., Walland A.C., Yeiser J.R., Cassis L., Carrillo J., et al. The soluble pattern recognition receptor PTX3 links humoral innate and adaptive immune responses by helping marginal zone B cells. J. Exp. Med. 2016;213:2167–2185. doi: 10.1084/jem.20150282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20150282</ArticleId><ArticleId IdType="pmc">PMC5030794</ArticleId><ArticleId IdType="pubmed">27621420</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Sullivan N.L., Rouphael N., Yu T., Banton S., Maddur M.S., McCausland M., Chiu C., Canniff J., Dubey S., et al. Metabolic Phenotypes of Response to Vaccination in Humans. Cell. 2017;169:862–877. doi: 10.1016/j.cell.2017.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.04.026</ArticleId><ArticleId IdType="pmc">PMC5711477</ArticleId><ArticleId IdType="pubmed">28502771</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagla I., Iliou A., Benaki D., Gikas E., Mikros E., Bagratuni T., Kastritis E., Dimopoulos M.A., Terpos E., Tsarbopoulos A. Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response. Cells. 2022;11:1241. doi: 10.3390/cells11071241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11071241</ArticleId><ArticleId IdType="pmc">PMC8997405</ArticleId><ArticleId IdType="pubmed">35406806</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C., Mohanty S., Kang H.A., Kong L., Avila-Pacheco J., Joshi S.R., Ueda I., Devine L., Raddassi K., Pierce K., et al. Metabolomic and transcriptomic signatures of influenza vaccine response in healthy young and older adults. Aging Cell. 2022;21:e13682. doi: 10.1111/acel.13682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13682</ArticleId><ArticleId IdType="pmc">PMC9470889</ArticleId><ArticleId IdType="pubmed">35996998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wensveen F.M., Šestan M., Wensveen T.T., Polić B. Beauty and the beast’ in infection: How immune–endocrine interactions regulate systemic metabolism in the context of infection. Eur. J. Immunol. 2019;49:982–995. doi: 10.1002/eji.201847895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847895</ArticleId><ArticleId IdType="pubmed">31106860</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>